25F-NBOMe

A synthetic psychedelic substance

25F-NBOMe
INN
Drug class
Routes of administration	Buccal, sublingual, nasal
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Uncontrolled
CAS Number	919797-20-9
PubChem	44469360
DrugBank
ChemSpider	23249980
KEGG

25F-NBOMe (2C-I-NBOMe) is a synthetic psychedelic substance from the NBOMe series, which is a derivative of the phenethylamine 2C-I. It is known for its potent hallucinogenic effects and is often used recreationally.

Chemical Structure and Properties

25F-NBOMe is a substituted phenethylamine with a methoxybenzyl group attached to the nitrogen atom. The chemical structure is characterized by the presence of a fluorine atom on the ethyl side chain, which distinguishes it from other compounds in the NBOMe series. The molecular formula is C18H22FNO3, and it has a molar mass of 319.37 g/mol.

Pharmacology

25F-NBOMe acts primarily as a potent agonist of the 5-HT2A receptor, which is the primary target for classical psychedelics such as LSD and psilocybin. The activation of this receptor is responsible for the psychedelic effects experienced by users. Due to its high potency, 25F-NBOMe is active at very low doses, often in the microgram range.

Effects

The effects of 25F-NBOMe are similar to those of other psychedelics, including visual and auditory hallucinations, altered perception of time, and changes in mood and thought patterns. The onset of effects is typically rapid, occurring within 30 to 90 minutes after administration, and can last for 6 to 10 hours.

Risks and Safety

25F-NBOMe is associated with significant risks, particularly due to its high potency and the difficulty in measuring accurate doses. Overdose can lead to severe adverse effects, including vasoconstriction, hypertension, tachycardia, and seizures. There have been reports of fatalities associated with the use of 25F-NBOMe, often due to accidental overdose.

Legal Status

The legal status of 25F-NBOMe varies by country. In some jurisdictions, it is classified as a controlled substance, while in others it remains unregulated. Users should be aware of the legal implications of possessing or distributing this compound in their region.

History and Research

25F-NBOMe was first synthesized in the early 2000s as part of research into the structure-activity relationships of phenethylamines. It gained popularity in the recreational drug market in the 2010s, often sold as a "legal high" or misrepresented as other psychedelics such as LSD.

Also see

• NBOMe series
• 2C-I
• Psychedelic drug
• 5-HT2A receptor
• LSD